Interview with Dr. Andrei Popov, CEO at Ecrins Therapeutics

24/04/2015 - 5 minutes

Screen Shot 2015-04-23 at 8.51.19 PM

Dr. Andrei Popov, CEO at Ecrins Therapeutics

Photo credit: Ecrins Therapeutics

Laureate of the 2002 INSERM program “Avenir”, Dr. Andrei Popov launched a research project with a focus on the mechanisms of cell division and bioactive small molecules, both fields relevant to oncology (INSERM and Joseph Fourier University in Grenoble). The discovery of several drug candidates by Drs. Aurélie Juhem and Andrei Popov allowed them, with the support of Prof. François Berger, to create in 2010 Ecrins Therapeutics. The project was awarded in 2009 the grant “Proof-of-concept” by the Lyon Auvergne Rhône-Alpes Cancéropôle and also won the National Innovation Contest for the Creation of Innovative Companies “Emergence” (2009) and “Création-Développement” (2010). The company aims to develop its drug candidates to clinical Proof-of- Concept. The lead drug candidate ET-D5 is a First-in-Class small molecule with an original anti-vascular and anti-proliferative mechanism of action.

– How your background leads you to start your own business?

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member